Carbimazole

Summary

Carbimazole (CHEMBL508102) is an approved small-molecule prodrug (ATC H03BB01); indicated across 2 conditions including thyroid gland disorder and thyrotoxicosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: H03BB01
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 186.23 Da · C7H10N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL508102
Name	Carbimazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	31072
ChEBI	CHEBI:617099
ATC	H03BB01
Molecular formula	C7H10N2O2S
Molecular weight	186.23
InChIKey	CFOYWRHIYXMDOT-UHFFFAOYSA-N

SMILES: CCOC(=O)N1C=CN(C1=S)C

IUPAC name: ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate

ChEBI definition: A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.

Pharmacological roles (ChEBI): prodrug, antithyroid drug.

Also known as: Carbimazol, Carbimazol henning, Carbimazole, Neo-mercazole 20, Neo-mercazole 5, NSC-758966, carbimazole, SID11112670, SID26749040, CARBIMAZOLE, SID144204147, SID170465583

Patent coverage: 991 distinct patent families (3,772 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prelamin-A/C, Cytochrome P450 1A2, Lactoperoxidase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.05	Potency	8912	nM	CHEMBL_ACT_3655183

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thyroid gland disorder	4	MONDO:0003240	HP:0000820
thyrotoxicosis	3	MONDO:0010138	EFO:0009190

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01436994	PHASE3	COMPLETED	Antithyroid Drug Treatment of Thyrotoxicosis in Young People
NCT00430547	Not specified	COMPLETED	Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).